Orphan Europe (UK) Ltd. Company Profile

18:39 EDT 25th September 2018 | BioPortfolio

Orphan Europe was started with the objective of providing orphan drugs to patients afflicted by rare disorders.Over the years an information network has been established to increase the awareness about rare disorders among healthcare professionals. The company has committed itself to provide support necessary to those working in this field. This is achieved through an extensive collaboration with experts in respective disease areas. Information and educational services can be provided upon request.
In another approach to strengthen the Orphan Drug status in Europe the company has provided input to the recently enacted European Orphan Drug Legislation.
We have highly experienced staff in our medical, regulatory and marketing departments with previous experience from major pharma companies. Being a small company allows us to be flexible and act rapidly. We are taking advantage of this rapid effective approach in our objective of providing healthcare professionals, and ultimately patients, with treatments for rare disorders.


Isis House 43 Station Road
United Kingdom


Phone: 44 (0) 1491 414 333
Fax: 44 (0) 1491 414 443

News Articles [448 Associated News Articles listed on BioPortfolio]

Research shows differences in orphan drug availability in Europe

A study suggests that the availability of orphan drugs varies significantly between different countries in Europe. Conducted by the University...Read More... The post Research shows differences in orp...

15% Reader Discount on Registration at the World Orphan Drug Congress Europe

The 9th annual World Orphan Drug Congress is the marketplace for orphan drug professionals looking at the complete value chain of orphan drug development, from clinical development and R&D to corp...

Disparity in availability of orphan meds in Europe

The availability of orphan medicines varies significantly between different European countries, a new…

Cytheris: Encouraging responses and orphan drug designation in Europe for CYT107 for the treatment of PML

In this episode of PharmaTelevision News Review, filmed at #BIO2012 Convention in Boston, Fintan Walton talks to Damian Marron, CEO of Cytheris about encouraging responses and orphan drug designatio...

Orphan drug status for new compound 'great news' says Amryt Pharma PLC's COO

Amryt Pharma PLC (LON:AMYT) has been granted orphan drug status in the US for  a compound called AP102 to treat patients with the excess growth condition acromegaly. Chief operating officer Ror...

Are Orphan Drugs Getting Too Much Attention By Payers And Policymakers?

Success of the Orphan Drug Act has brought with it pushback from payers, policymakers, and legislators. Pushback may be warranted in some instances. But, a case-by-case approach examining the value of...

Martin Pharmaceuticals’ Linvantra Receives FDA Orphan Drug Designation in Second Indication

NewsThe company has been granted Orphan Drug Designation by the FDA Livantra in the treatment of Pulmonary Arterial Hypertension.

Prescribe Robust Distribution to Commercialize Your Orphan Drug

Finding a home for your biopharmaceutical company’s new orphan drug doesn’t just happen after it is FDA approved. The successful commercialization of your promising new drug requires a focused and...

Drugs and Medications [8 Associated Drugs and Medications listed on BioPortfolio]

Nasal decongestant [SUPERVALU INC.]

Equaline 44-112

Carbaglu [Orphan Europe, SARL]

These highlights do not include all the information needed to use CARBAGLU safely and effectively.  See full prescribing information for CARBAGLU.   CARBAGLU (carglumic acid) TabletsInitial U.S. App...

Nizatidine [Dispensing Solutions Inc.]

Nizatidine Capsules USP Rx only


Akne-mycin (Erythromycin)

Kepivance [Swedish Orphan Biovitrum AB (publ)]

These highlights do not include all the information needed to use Kepivance safely and effectively. See full prescribing information for Kepivance.Kepivance® (palifermin) For injection, for intraveno...

PubMed Articles [398 Associated PubMed Articles listed on BioPortfolio]

Orphan drugs: trends and issues in drug development.

Research in rare diseases has contributed substantially toward the current understanding in the pathophysiology of the common diseases. However, medical needs of patients with rare diseases have alway...

Insights into the Pharmaceuticals and Mechanisms of Neurological Orphan Diseases: Current Status and Future Expectations.

Several rare or orphan diseases have been characterized that singly affect low numbers of people, but cumulatively reach ∼6% - 10% of the population in Europe and in the United States. Human genetic...

Dose-Finding Studies Among Orphan Drugs Approved in the EU: A Retrospective Analysis.

In the development process for new drugs, dose-finding studies are of major importance. Absence of these studies may lead to failed phase 3 trials and delayed marketing authorization. In our study we ...

The genomic history of southeastern Europe.

Farming was first introduced to Europe in the mid-seventh millennium bc, and was associated with migrants from Anatolia who settled in the southeast before spreading throughout Europe. Here, to unders...

Towards the risk of Yellow Fever transmission in Europe.

Yellow fever (YF) is an emerging expanding fatal arboviral disease that has been imported at least six times in Europe during the first half of 2018, while only seven travel-associated YF cases have b...

Clinical Trials [638 Associated Clinical Trials listed on BioPortfolio]

Safety and Feasibility of Normothermic Machine Perfusion to Rescue Orphan Livers

Orphan livers are organs that have been declined for clinical use by all centers due to their marginality. The current standard of care of liver preservation before transplant is cold stor...

Orphan Europe Carbaglu® Surveillance Protocol

The purpose of this study is to conduct post-marketing surveillance of carglumic acid (Carbaglu) to obtain long-term clinical safety information. Carglumic acid was approved by the United ...

Lentiviral-mediated Gene Therapy of Fanconi Anemia Patients Subtype A

This is an open, Phase I / II clinical trial to evaluate the safety and efficacy of a hematopoietic gene therapy procedure with an orphan drug consisting of a lentiviral vector carrying th...

In-market Utilisation of Liraglutide Used for Weight Management in Europe: a Retrospective Medical Record Review Study

This study is conducted in Europe. The aim of this study is to investigate usage of liraglutide for weight management in clinical practice.

Description/Characterisation of Asthmatics Eligible for Biologic Therapy Referral in Prim. and Sec. Care in Europe

This is a multi-country, multicentre, observational cross-sectional one-visit study of patients with severe asthma in primary and secondary care settings in Europe

Companies [957 Associated Companies listed on BioPortfolio]

AOP Orphan Pharmaceuticals AG

AOP Orphan is a multinational company with headquarters in Vienna, Austria, focusing on clinical research, development and distribution of medicines for rare and complex diseases....

Orphan Europe (UK) Ltd.

Orphan Europe was started with the objective of providing orphan drugs to patients afflicted by rare disorders.Over the years an information network has been established to increase the awareness abou...

Orphan Medical Incorporated

Orphan Medical Incorporated is a development stage company, was formed to acquire, develop and market products of high medical value intended to address inadequately treated or uncommon diseases of we...

Santhera Pharmaceuticals Holding Ltd

Santhera Pharmaceuticals is a Swiss biopharmaceutical company focusing on the discovery, development and marketing of small molecule pharmaceutical products for the treatment of neuromuscular diseases...

Orphan Technologies

Orphan Technologies is dedicated to developing novel therapies to dramatically improve the lives of patients suffering from the rare disorder, homocystinuria and related diseases....

More Information about "Orphan Europe (UK) Ltd." on BioPortfolio

We have published hundreds of Orphan Europe (UK) Ltd. news stories on BioPortfolio along with dozens of Orphan Europe (UK) Ltd. Clinical Trials and PubMed Articles about Orphan Europe (UK) Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Orphan Europe (UK) Ltd. Companies in our database. You can also find out about relevant Orphan Europe (UK) Ltd. Drugs and Medications on this site too.

Quick Search


Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Corporate Database Quicklinks

Searches Linking to this Company Record